• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors.

作者信息

Pollack A, Zagars G K, Swanson D A

机构信息

Department of Clinical Radiotherapy, University of Texas-M.D. Anderson Cancer Center, Houston 77030.

出版信息

Int J Radiat Oncol Biol Phys. 1994 Sep 30;30(2):267-77. doi: 10.1016/0360-3016(94)90004-3.

DOI:10.1016/0360-3016(94)90004-3
PMID:7928456
Abstract

PURPOSE

To determine the relationship of several potential prognostic factors to the outcome measures of pelvic control, freedom from metastases, and overall survival for bladder cancer patients treated with definitive external beam radiotherapy.

METHODS AND MATERIALS

The records of 135 patients treated with high-dose, planned continuous-course, external beam radiotherapy for muscle-invasive transitional cell bladder cancer were reviewed. These patients were treated to an average total dose of 6588 +/- 475 cGy with an average fractional dose of 207 +/- 18 cGy using megavoltage. Median potential follow-up for all patients, including those who died, was 249 months.

RESULTS

The actuarial results at 5 year were 31% pelvic control, 58% freedom from metastases, and 26% overall survival. In the univariate analyses, several factors were correlated with disease outcome including clinical stage, tumor morphology, gross total transurethral resection (TURBT), findings at bimanual exam after TURBT, clinical perivesical extension, age, and clinical complete response at first follow-up cystoscopy (Clinical-CR). A Cox proportional hazards model revealed that only Clinical-CR was independently predictive of pelvic control. In terms of freedom from metastases, only Clinical-CR and clinical stage were significantly associated with outcome in the multivariate analysis. When the multivariate analysis was restricted to T2 and T3 tumors only, then clinical perivesical extension replaced stage as being associated with freedom from metastases. The only factors significantly related to overall survival in the Cox proportional hazards model were Clinical-CR, age, and complete TURBT; stage was of borderline significance when only pretreatment factors were considered.

CONCLUSIONS

Clearly, the most important prognostic factor was Clinical-CR. The pretreatment factors of stage, clinical perivesical extension, and gross total TURBT also correlated with outcome, but, to a lesser degree. For patients medically unfit for radical cystectomy radiotherapy is a viable option, particularly for selected patients. Patients with T4 tumors are poor candidates for definitive radiotherapy and should be treated palliatively if they cannot tolerate systemic therapy.

摘要

相似文献

1
Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors.
Int J Radiat Oncol Biol Phys. 1994 Sep 30;30(2):267-77. doi: 10.1016/0360-3016(94)90004-3.
2
Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone.肌层浸润性膀胱癌的局部控制:术前放疗联合膀胱切除术与单纯膀胱切除术的比较。
Int J Radiat Oncol Biol Phys. 1995 May 15;32(2):331-40. doi: 10.1016/0360-3016(95)00086-E.
3
Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients.肌层浸润性膀胱癌的术前放疗。338例患者的长期随访及预后因素
Cancer. 1994 Nov 15;74(10):2819-27. doi: 10.1002/1097-0142(19941115)74:10<2819::aid-cncr2820741013>3.0.co;2-l.
4
Muscle-invasive bladder cancer treated with external beam radiotherapy: pretreatment prognostic factors and the predictive value of cystoscopic re-evaluation during treatment.
Radiother Oncol. 1998 Nov;49(2):149-55. doi: 10.1016/s0167-8140(98)00089-9.
5
Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy.对于不适合进行根治性膀胱切除术的肌肉浸润性膀胱癌患者,采用顺铂与放疗同步治疗。
J Urol. 1996 Oct;156(4):1258-62.
6
Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy.p53在术前放疗治疗的肌层浸润性膀胱癌中的预后价值。
Urology. 1996 Mar;47(3):305-10. doi: 10.1016/s0090-4295(99)80443-9.
7
Treatment results of radiation therapy for muscle-invasive bladder cancer.肌层浸润性膀胱癌放射治疗的疗效。
Strahlenther Onkol. 2010 Apr;186(4):203-9. doi: 10.1007/s00066-010-2053-1. Epub 2010 Mar 26.
8
Radical radiotherapy and salvage cystectomy as the primary management of transitional cell carcinoma of the bladder. Results following the introduction of a CT planning technique.根治性放射治疗和挽救性膀胱切除术作为膀胱移行细胞癌的主要治疗方法。引入CT规划技术后的结果。
Clin Oncol (R Coll Radiol). 2002 Apr;14(2):141-7. doi: 10.1053/clon.2002.0055.
9
Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.顺铂与多西他赛同步化疗联合外照射根治性放疗用于浸润性移行细胞膀胱癌患者:耐受性及局部控制的初步报告
Anticancer Res. 1997 Nov-Dec;17(6D):4771-80.
10
Radical radiotherapy for bladder cancer: retrospective analysis of a series of 459 patients treated in an Italian institution.
Clin Oncol (R Coll Radiol). 2006 Feb;18(1):52-9. doi: 10.1016/j.clon.2005.06.015.

引用本文的文献

1
Bladder-sparing approaches for muscle invasive bladder cancer: a narrative review of current evidence and future perspectives.肌肉浸润性膀胱癌的保膀胱治疗方法:当前证据与未来展望的叙述性综述
Transl Androl Urol. 2023 May 31;12(5):802-808. doi: 10.21037/tau-23-124. Epub 2023 May 26.
2
Survival Impact of Current-Smoking-Related COPD or COPD with Acute Exacerbation on Bladder Preservation through Concurrent Chemoradiotherapy for Muscle-Invasive Bladder Urothelial Carcinoma.当前吸烟相关慢性阻塞性肺疾病(COPD)或伴有急性加重的COPD对肌层浸润性膀胱尿路上皮癌同步放化疗保膀胱的生存影响。
J Pers Med. 2021 Sep 26;11(10):958. doi: 10.3390/jpm11100958.
3
Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART) - A study protocol for an open-label, phase II, multicenter study.
阿替利珠单抗联合放疗用于浸润性膀胱癌的膀胱保留疗法(BPT-ART)——一项开放标签、II期、多中心研究的研究方案
Contemp Clin Trials Commun. 2021 Jan 21;21:100724. doi: 10.1016/j.conctc.2021.100724. eCollection 2021 Mar.
4
Bladder preservation in muscle-invasive bladder cancer: a comprehensive review.肌层浸润性膀胱癌的膀胱保留治疗:全面综述。
Int Braz J Urol. 2020 Mar-Apr;46(2):169-184. doi: 10.1590/S1677-5538.IBJU.2020.99.01.
5
Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.膀胱癌保留膀胱的三联疗法治疗肌层浸润性膀胱癌。
Curr Oncol Rep. 2018 Jun 30;20(9):66. doi: 10.1007/s11912-018-0711-0.
6
Landmarks in the treatment of muscle-invasive bladder cancer.肌层浸润性膀胱癌的治疗里程碑。
Nat Rev Urol. 2017 Sep;14(9):565-574. doi: 10.1038/nrurol.2017.82. Epub 2017 Jul 4.
7
The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer.经尿道切除术在肌层浸润性膀胱癌三联疗法中的作用。
Bladder Cancer. 2016 Oct 27;2(4):381-394. doi: 10.3233/BLC-160076.
8
Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers.肌肉浸润性膀胱癌的膀胱保留治疗方法
Curr Treat Options Oncol. 2016 Mar;17(3):15. doi: 10.1007/s11864-016-0390-8.
9
Effective bladder preservation strategy with low-dose radiation therapy and concurrent intraarterial chemotherapy for muscle-invasive bladder cancer.低剂量放射治疗联合同期动脉内化疗用于肌层浸润性膀胱癌的有效膀胱保留策略
Radiat Med. 2008 Apr;26(3):156-63. doi: 10.1007/s11604-007-0211-x.
10
Combined chemotherapy and external beam radiotherapy for transitional cell carcinoma of the bladder.联合化疗与体外照射放疗治疗膀胱移行细胞癌
Curr Oncol Rep. 2004 May;6(3):230-6. doi: 10.1007/s11912-004-0054-x.